drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Fresh donor-derived, second-generation CD19-directed CAR T cells (lentiviral-transduced) that express a CAR with CD3ΞΆ and a costimulatory domain to recognize CD19 on B cells, leading to T-cell activation, proliferation, cytotoxic killing of CD19+ cells, and expected B-cell aplasia.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic, lentiviral-transduced T cells engineered with a second-generation anti-CD19 CAR (CD3z plus a costimulatory domain) recognize CD19 on B cells, leading to T-cell activation, proliferation, and cytotoxic killing of CD19+ cells, with expected on-target B-cell aplasia.
drug_name
CD19-CAR_Lenti_ALLO
nct_id_drug_ref
NCT06080191